Preeclampsia: Universal Screening or Universal Prevention for Low andMiddle-Income Settings?

Dear Editor,

We read with interest the Clinical Consensus Recommendation about screening and prevention of preeclampsia published by De Oliveira et al.¹ The authors recommend that identification of high-risk women should be based on maternal risk factors alone, and that universal treatment (of all pregnant women) with aspirin at a dose of 100 mg should be considered in low- and middle-income countries. In this letter, we express our concerns and disagreement with these strategies.

The association of certain maternal risk factors with an increased risk of preeclampsia development is well known, and several risk scoring systems have been recommended by Obstetric societies around the world, such as the National Institute for Health and Care Excellence (NICE) criteria in the United Kingdom, and the American College of Obstetrician and Gynecologists (ACOG) in the United States. Such scoring systems are based on experts' opinions and low levels of evidence, attribute similar weights to very different risk factors, and perform poorly in the clinical practice.¹ Recent large studies² have shown that such methods fail to identify as high-risk 60% to 70% of women who will later develop preeclampsia. Furthermore, physician compliance with these recommendations is low, with only 20% to 30% of high-risk women receiving aspirin prophylaxis.^2,3 On the other hand, combined screening with individual risk calculation by incorporating risk factors, mean arterial blood pressure, uterine artery Doppler studies, and placental growth factor (PlGF) far outperforms risk scoring, identifying as high-risk about three quarters of women who will develop preterm preeclampsia, and 90% of those destined to develop early-onset disease.^4,5 In addition, combined screening is more cost-effective,⁶ and is associated with nearly total physician compliance.³ Although resistance to new technologies is common in Medicine, and translation of research into clinical practice usually takes a long time,⁷ most components of combined screening, such as the measurement of arterial blood pressure and ultrasound are readily available and widely in use in most settings (even in low/middle-income countries). Simplified versions of the algorithm (for example, without biochemical markers) outperformed clinical history even in middle-income countries such as Brazil,^8,9 and could be rapidly implemented with minimal or no increase in cost, and lead to a significant increase in the detection of high-risk women who would benefit from aspirin prophylaxis and likely be missed by risk scoring screening.

As appealing as the suggestion to give aspirin to all pregnant women given its relative safety and low cost may be, a strategy of universal aspirin use has not been properly assessed in adequately-powered prospective studies.¹⁰ Pregnant women are naturally resistant to medication use in the absence of convincing medical indication, and such an approach would likely be associated with low adherence to treatment.¹⁰ The strong effect of aspirin in the prevention of preeclampsia in high-risk populations¹¹ may not be observed when the treatment is recommended to the entire obstetric population, and side effects will inevitably become more frequent if millions of women are treated. Indeed, data from a previous study on universal aspirin prophylaxis demonstrated no clear treatment benefit,^12,13 increased risk of postpartum hemorrhage,¹⁴ and other hemorrhagic events,¹² as well as low adherence to treatment.¹² We argue that early combined prediction with the full or simplified versions of the algorithm for individual risk calculation is feasible in low- and middle-income countries, and should be the preferred method of screening whenever possible, in line with recent recommendations from the International Federation of Gynecology and Obstetrics (FIGO),¹⁵ the International Society for the Study of Hypertension in Pregnancy (ISSHP),¹⁶ and the International Society of Ultrasound in Obstetrics and Gynecology.¹⁷

References

• ¹ De Oliveira LG, Diniz ALD, Prado CAC, Da Cunha Filho EV, De Souza FLP, Korkes HA, et al. Pre-eclampsia: universal screening or universal prevention for low and middle-income settings? Rev Bras Ginecol Obstet. 2021;43(01):61-65. Doi: 10.1055/s-0040-1713803
  » https://doi.org/10.1055/s-0040-1713803
• ² Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for preeclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51(06):743-750. Doi: 10.1002/uog.19039
  » https://doi.org/10.1002/uog.19039
• ³ Guy GP, Leslie K, Diaz Gomez D, Forenc K, Buck E, Khalil A, Thilaganathan B. Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study. BJOG. 2021;128(02):149-156. Doi: 10.1111/1471-0528.16361
  » https://doi.org/10.1111/1471-0528.16361
• ⁴ Rolnik DL, Wright D, Poon LCY, Syngelaki A, O'Gorman N, Matallana CP, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(04): 492-495. Doi: 10.1002/uog.18816
  » https://doi.org/10.1002/uog.18816
• ⁵ O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, et al. Accuracy of competing-risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2017;49(06):751-755. Doi: 10.1002/uog.17399
  » https://doi.org/10.1002/uog.17399
• ⁶ Park F, Deeming S, Bennett N,Hyett J. Cost effectiveness analysis of a model of first trimester prediction and prevention for preterm preeclampsia against usual care. Ultrasound Obstet Gynecol. 2020;•••;. Doi: 10.1002/uog.22193[ahead of print]
  » https://doi.org/10.1002/uog.22193
• ⁷ Papageorghiou AT. From evidence to implementation. BJOG. 2020;127(10):1173-1174. Doi: 10.1111/1471-0528.16408
  » https://doi.org/10.1111/1471-0528.16408
• ⁸ Rocha RS, Alves JAG, E Holanda Moura SBM, Araujo EJúnior, Peixoto AB, Santana EFM, et al. Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy. J Perinat Med. 2017;45(07):843-849. Doi: 10.1515/jpm-2016-0418
  » https://doi.org/10.1515/jpm-2016-0418
• ⁹ Rocha RS, Gurgel Alves JA, E Holanda Moura SBM, Araujo EJúnior, Martins WP, Vasconcelos CTM, et al. Comparison of three algorithms for prediction preeclampsia in the first trimester of pregnancy. Pregnancy Hypertens. 2017;10:113-117. Doi: 10.1016/j.preghy.2017.07.146
  » https://doi.org/10.1016/j.preghy.2017.07.146
• ¹⁰ Cuckle H. Strategies for prescribing aspirin to prevent preeclampsia: a cost-effectiveness analysis. Obstet Gynecol. 2020;135(01): 217. Doi: 10.1097/AOG.0000000000003631
  » https://doi.org/10.1097/AOG.0000000000003631
• ¹¹ Rolnik DL,Wright D, Poon LC, O'Gorman N, Syngelaki A, Matallana CP, et al. Aspirin versus placebo in pregnancies at high risk for pretermpreeclampsia. N Engl J Med. 2017;377(07):613-622. Doi: 10.1056/NEJMoa1704559
  » https://doi.org/10.1056/NEJMoa1704559
• ¹² Subtil D, Goeusse P, Puech F, Lequien P, Biausque S, Breart G, et al; Essai Régional Aspirine Mère-Enfant (ERASME) Collaborative Group. Aspirin (100mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). BJOG. 2003;110(05):475-484. Doi: 10.1046/j.1471-0528.2003.02096.x
  » https://doi.org/10.1046/j.1471-0528.2003.02096.x
• ¹³ Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, et al; ASPIRIN Study Group. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10220):285-293. Doi: 10.1016/S0140-6736(19)32973-3
  » https://doi.org/10.1016/S0140-6736(19)32973-3
• ¹⁴ Mone F, Mulcahy C, McParland P, Breathnach F, Downey P, McCormack D, et al. Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial. BMJ Open. 2018;8(07):e022056. Doi: 10.1136/bmjopen-2018-022056
  » https://doi.org/10.1136/bmjopen-2018-022056
• ¹⁵ Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145 (Suppl 1):1-33. Doi: 10.1002/ijgo.12802
  » https://doi.org/10.1002/ijgo.12802
• ¹⁶ Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al; International Society for the Study of Hypertension in Pregnancy (ISSHP) Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(01):24-43. Doi: 10.1161/HYPERTENSIONAHA.117.10803
  » https://doi.org/10.1161/HYPERTENSIONAHA.117.10803
• ¹⁷ Sotiriadis A, Hernandez-Andrade E, da Silva Costa F, Ghi T, Glanc P, Khalil A, et al; ISUOG CSC Pre-eclampsia Task Force. ISUOG Practice Guidelines: role of ultrasound in screening for and follow-up of pre-eclampsia. Ultrasound Obstet Gynecol. 2019; 53(01):7-22. Doi: 10.1002/uog.20105
  » https://doi.org/10.1002/uog.20105

Author’s Reply:

AuthorshipSCIMAGO INSTITUTIONS RANKINGS

Dear Editor,

We are grateful to the colleague who raised the questions related to our recent publication regarding the use of aspirin and calcium for the prevention of preeclampsia in low- and middle-income countries.¹ Discussions like this are fundamental to raise the importance of the topic, which represents the main cause of maternal death in Brazil. However, we are not sure that the colleague has fully understood our publication, since the costs related to prevention are important, but only part of our text.

We initially expressed great uncertainty regarding the impact of using any algorithms currently demonstrated for the screening of preeclampsia. This is remarkable, since a complex screening model, involving biophysical, biochemical markers, and maternal data recently identified only 0.26% of women who would be diagnosed with preterm preeclampsia in a huge population.² The colleague then suggested that protocol adaptations using less complex algorithms according to the economic possibilities of each location could be implemented. However, Prefumo and Farina³ (2017) raised important considerations about the addition of markers to increase the sensitivity of clinical data in the prediction of preeclampsia. Interestingly, the addition of just one biophysical or biochemical marker does not increase the detection rates, since confidence intervals clearly overlap in most large studies. In the study by O'Gorman et al.⁴ (2017), for example, the simple addition of the mean arterial pressure was as efficient as the addition of the uterine artery Doppler or placental growth factor (PlGF) in the prediction of preeclampsia before 32 weeks, with a false-positive rate of 10%. Recently, Sovio and Smith⁵ (2019) developed a simple risk score using the same maternal characteristics used for the original algorithm in the Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention (ASPRE) study.²⁵ The area under the receiver operating characteristic (ROC) curve of this simplified score was of 0.846 (95% confidence interval [95%CI]: 0.787–0.906), similar to that of the complete algorithm, which was of 0.854 (95%CI: 0.795–0.914). In addition to the fact that there actually is no efficient algorithm for the prediction of preeclampsia, we speculate that the discussion regarding the use of these complex algorithms may contribute to divert the attention of many clinicians regarding important epidemiological information, leading to low rates of prescription of aspirin and calcium.

The colleague who brings the questions refers elusively about the results regarding the use of aspirin. Therefore, we request caution when studying this issue. When referring to the article published by Hoffman et al.⁶ (2020), the colleague should have noticed the enormous impact of this study when the authors demonstrated that nulliparous women from low and middle-income countries who started using aspirin in the period between 6 and 13 weeks and 6 days of pregnancy had a lower incidence of preterm birth and a reduction in perinatal mortality, without adverse effects.⁶ Simple and safe, as mentioned by Quinlivan⁷ (2020).

Regarding safety, the colleague also raised a question about the increased risk of bleeding among women using aspirin in two studies. The study published by Subtil et al.⁸ (2003) demonstrated that there was no difference regarding adverse outcomes between the aspirin (19.5%) and placebo (15.8%) groups (relative risk [RR]: 1.23; 95%CI: 1.06–1.43) as the CI reached the null line. Specifically regarding bleeding-related events, such as epistaxis, metrorrhagia and minimal bleeding from the digestive tract, these were considered minimal by the authors. Additionally, when analyzing the results, we realize that the CI also touched the null line (11.6% versus 9.3%; RR: 1.25; 95%CI: 1.03–1.54).

The study developed by Mone et al. (2018),⁹ also cited by the colleague as reporting increased numbers of hemorrhagic events, was a feasibility study with no power for this conclusion. Even so, the colleague should be more cautious, since Mone et al. ⁹ reported in their safety results that the bleeding cases were spottings unrelated to miscarriages, and that there was only a small number of women who had postpartum bleeding (n = 20 without aspirin; n = 26 with aspirin). In conclusion, the authors also pointed out that there was no difference regarding hemoglobin levels < 8 g/dL or need for blood transfusion. Finally, this study demonstrated that even low-risk nulliparous women would be happy to take aspirin, which currently contradicts concerns about the low adherence to this medication. In our interpretation, this adherence relates to the impact of the disease on a specific population, which is huge for low- and middle-income countries. Additionally, if clinicians stopped being confused by those who want to introduce complex algorithms for the prediction of preeclampsia, they would prescribe more aspirin and calcium.

We understand that screenings with innovative technologies such as ultrasound or biological markers are very attractive, but are not feasible in low- and middle-income countries, especially in countries with large territorial areas and huge disparities in terms of resources. The women who actually die in these countries are those with lowest socioeconomic status, and our main efforts must converge to really reach this population to provide basic conditions instead of expensive and useless ones.

Mallampati et al.¹⁰ (2019) developed an elegant study comparing the non-use of aspirin, the use of aspirin by women with positive screening based on biomarkers and Doppler, the use of aspirin based on the presence of clinical markers (USA-Task Force), and the universal use of aspirin in pregnancy. The authors demonstrated that the universal use of aspirin significantly reduced the incidence of preterm preeclampsia when compared with the non-use (805 less cases in 100,000 women), when compared with the use of Doppler and biomarkers (314 less cases in 100,000 women), or when compared with clinical screening (358 less cases in 100,000 women). In addition to improving adherence to prevention, the universal use of aspirin has shown a better cost-benefit ratio, without increasing the incidence of adverse events.

In addition, when the colleague mentions that combined screening does not increase costs, he does not seem to believe that this screening model during the first trimester may even lead to additional concerns, as increased number of antenatal visits, additional tests, and, unfortunately, iatrogenic preterm deliveries due to “altered screening.” All of this using methodologies with little evidence of clinical applicability, as published in the systematic review recently published by De Kat et al. (2019).¹¹

Finally, when the colleague mentions that combined screening is part of the International Federation of Gynecology and Obstetrics (FIGO) recommendations, he or she refers to the publication by Poon et al.¹² (2019). However, the following recommendations have been displayed on the FIGO web site (https://www.figo.org/figo-releases-new-guidelines-combat-pre-eclampsia):

“All pregnant women should be screened for preterm PE [preeclampsia] during early pregnancy in the first-trimester with maternal risk factors and blood pressure. Biomarkers offer a potential for early diagnosis and effective treatment, however, the global community recognizes that further evidence for its applicability in all populations and ethnic groups is required at this stage.

While several studies have evaluated the role of biomarkers or a combination of physical and chemical measurements, further studies are needed to define their additional role in improving early prediction of preterm PE.

FIGO encourages all countries and its member associations to adopt and promote strategies to ensure quality research and eventual consensus.”

Regarding the recommendation by the International Society for the Study of Hypertension in Pregnancy ISSHP also mentioned, this society clearly manifested that first trimester screening could be integrated to health systems with capacity for this, and stressed that cost-effectiveness should be evaluated.¹³ Additionally, the ISSHP did not mention anything specifically to low and middle-income settings, and we know that this society is truly aware about all difficulties that such countries have.

Essentially, what often seem to be innovative technologies in the clinical practice may not be cost-effective, may not reach vulnerable populations, and may compromise feasible protocols. At this point, we need to be pragmatic and realistic to support public policies based on the best scientific evidence, to reduce maternal mortality related to preeclampsia in low- and middle-income countries.

References

• ¹ De Oliveira LG, Diniz ALD, Prado CAC, Da Cunha Filho EV, De Souza FLP, Korkes HA, et al. Pre-eclampsia: universal screening or universal prevention for low and middle-income settings? Rev Bras Ginecol Obstet. 2021;43(01):61-65. Doi: 10.1055/s-0040-1713803
  » https://doi.org/10.1055/s-0040-1713803
• ² Rolnik DL, Wright D, Poon LCY, Syngelaki A, O'Gorman N, Matallana CP, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50(04): 492-495. Doi: 10.1002/uog.18816
  » https://doi.org/10.1002/uog.18816
• ³ Prefumo F, Farina A. First-trimester screening for pre-eclampsia: time for reflection. Ultrasound Obstet Gynecol. 2017;50(05): 662-663. Doi: 10.1002/uog.18893
  » https://doi.org/10.1002/uog.18893
• ⁴ O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Alvarado Mde, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017;49(06):756-760. Doi: 10.1002/uog.17455
  » https://doi.org/10.1002/uog.17455
• ⁵ SovioU,SmithG. Evaluationofa simple risk score to predict preterm pre-eclampsia usingmaternal characteristics: a prospective cohort study. BJOG. 2019;126(08):963-970. Doi: 10.1111/1471-0528.15664
  » https://doi.org/10.1111/1471-0528.15664
• ⁶ Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, et al; ASPIRIN Study Group. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395(10220):285-293. Doi: 10.1016/S0140-6736(19)32973-3
  » https://doi.org/10.1016/S0140-6736(19)32973-3
• ⁷ Quinlivan JA. Simple and safe: preventing preterm birth with aspirin. Lancet. 2020;395(10220):250-252. Doi: 10.1016/S0140-6736(20)30106-9
  » https://doi.org/10.1016/S0140-6736(20)30106-9
• ⁸ Subtil D, Goeusse P, Puech F, Lequien P, Biausque S, Breart G, et al; Essai Régional Aspirine Mère-Enfant (ERASME) Collaborative Group. Aspirin (100mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). BJOG. 2003;110(05):475-484. Doi: 10.1046/j.1471-0528.2003. 02096.x
  » https://doi.org/10.1046/j.1471-0528.2003
• ⁹ Mone F, Mulcahy C, McParland P, Breathnach F, Downey P, McCormack D, et al. Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial. BMJ Open. 2018;8(07):e022056. Doi: 10.1136/bmjopen-2018-022056
  » https://doi.org/10.1136/bmjopen-2018-022056
• ¹⁰ Mallampati D, Grobman W, Rouse DJ, Werner EF. Strategies for prescribing aspirin to prevent preeclampsia: a cost-effectiveness analysis. Obstet Gynecol. 2019;134(03):537-544. Doi: 10.1097/AOG.0000000000003413
  » https://doi.org/10.1097/AOG.0000000000003413
• ¹¹ De Kat AC, Hirst J,Woodward M, Kennedy S, Peters SA. Prediction models for preeclampsia: A systematic review. Pregnancy Hypertens. 2019;16:48-66. Doi: 10.1016/j.preghy.2019.03.005
  » https://doi.org/10.1016/j.preghy.2019.03.005
• ¹² Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145 (Suppl 1):1-33. Doi: 10.1002/ijgo.12802
  » https://doi.org/10.1002/ijgo.12802
• ¹³ Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al; International Society for the Study of Hypertension in Pregnancy (ISSHP) Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(01):24-43. Doi: 10.1161/HYPERTENSIONAHA.117.10803
  » https://doi.org/10.1161/HYPERTENSIONAHA.117.10803

Publication Dates

• Publication in this collection
  18 June 2021
• Date of issue
  Apr 2021